

## Short Communication

# Cellular senescence predicts treatment outcome in metastasised colorectal cancer

AM Haugstetter<sup>1</sup>, C Loddenkemper<sup>2,3</sup>, D Lenze<sup>2</sup>, J Gröne<sup>4</sup>, C Standfuß<sup>5</sup>, I Petersen<sup>6</sup>, B Dörken<sup>1,7</sup> and CA Schmitt<sup>\*,1,7</sup>

<sup>1</sup>Medical Department of Hematology, Oncology and Tumor Immunology, Molekulares Krebsforschungszentrum der Charité – MKFZ, Charité – Universitätsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany; <sup>2</sup>Institute of Pathology, Technische Universität München, Munich, Germany; <sup>3</sup>Department of Pathology, Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin, Berlin, Germany; <sup>4</sup>Department of General, Vascular and Thoracic Surgery, Campus Benjamin Franklin, Charité – Universitätsmedizin Berlin, Berlin, Germany; <sup>5</sup>Department of Bioinformatics, Free University, Berlin, Germany; <sup>6</sup>Department of Pathology, Friedrich Schiller University, Jena, Germany; <sup>7</sup>Max-Delbrück-Center for Molecular Medicine, Berlin, Germany

**BACKGROUND:** Cellular senescence is a terminal cell-cycle arrest that occurs in response to activated oncogenes and DNA-damaging chemotherapy. Whether cancer cell senescence at diagnosis might be predictive for treatment outcome is unknown.

**METHODS:** A senescence index (SI) was developed and used to retrospectively correlate the treatment outcome of 30 UICC stage IV colorectal cancer (CRC) patients with their SI at diagnosis.

**RESULTS:** 5-Fluorouracil/leucovorin-treated CRC patients achieved a significantly longer progression-free survival when presenting with SI-positive tumours before therapy (median 12.0 vs 6.0 months;  $P = 0.044$ ).

**CONCLUSION:** Cancer cell senescence predicts treatment outcome in metastasised CRC. Prospective analyses of larger patient cohorts are needed.

*British Journal of Cancer* (2010) **103**, 505–509. doi:10.1038/sj.bjc.6605784 www.bjcancer.com

Published online 13 July 2010

© 2010 Cancer Research UK

**Keywords:** cellular senescence; colorectal cancer; Ras mutations; treatment outcome

In the past, many cancer studies sought to link quantitative assessments of tumour growth properties, namely proliferation and apoptosis, to treatment outcome, but the majority of these analyses produced negative results for various reasons. Although relevant as a prognosticator, the value of using the mitotic index to predict treatment outcome is very limited (see Schmitt, 2003, 2007; Brown and Attardi, 2005; Yerushalmi *et al*, 2010 and references therein for review). A third cancer-related growth condition is oncogene-induced senescence (OIS), a terminal cell-cycle arrest initiated by activated Ras-type oncogenes that functions as a tumour-suppressive barrier in pre-malignant lesions *in vivo* (Braig *et al*, 2005; Michaloglou *et al*, 2005; Collado and Serrano, 2010; Reimann *et al*, 2010). Oncogene-induced senescence is mediated through an oncogene-evoked DNA damage response (DDR) (Bartkova *et al*, 2005, 2006; Gorgoulis *et al*, 2005), thereby explaining why DNA-damaging chemotherapy produces senescence as well (Chang *et al*, 1999; Schmitt *et al*, 2002). Therapy-induced senescence (TIS) contributes to treatment outcome in pre-clinical models (Schmitt *et al*, 2002), and is detectable in patient cancer biopsies after neoadjuvant chemotherapy (te Poele *et al*, 2002; Roberson *et al*, 2005), but its long-term effect on clinical courses remains undetermined. We hypothesised that senescent cells present sporadically in untreated cancers at diagnosis may indicate an increased susceptibility to TIS, and, thus, might be associated with a superior clinical outcome. Because

the gold-standard senescence assay, detection of the senescence-associated  $\beta$ -galactosidase (SA- $\beta$ -gal) activity (Dimri *et al*, 1995), cannot be applied to formalin-fixed and paraffin-embedded (FFPE) clinical routine samples, we developed a senescence index (SI) based on FFPE-suitable immunohistochemical surrogate markers. We report here the first-time use of this SI in untreated human tumour specimens at diagnosis as a predictor for outcome to cancer therapy.

## MATERIALS AND METHODS

### Patients and tumour material

Snap-frozen or FFPE samples of normal colon mucosa, colon adenoma and colon carcinoma were collected, and informed patient consent was obtained for the anonymous use of the material. FFPE tumour samples from previously untreated 30 patients with UICC stage IV colorectal cancer (CRC) all of whom received a 5-fluorouracil/leucovorin (5-FU/LV)-based first-line regimen were subjected to senescence evaluation, reflecting the available archive material in our pathology department between the years 1996 and 2002 that met these criteria. Tissue material from patients suspected or diagnosed with a hereditary cancer syndrome or inflammatory bowel disease, or whose chemotherapy was terminated for reasons other than disease progression was excluded from this study. Clinical data sets were compiled in a retrospective and anonymous manner, and included gender, age, tumour location, carcinoembryonic antigen (CEA) serum levels,

\*Correspondence: Dr CA Schmitt; E-mail: clemens.schmitt@charite.de  
Received 15 April 2010; revised 10 June 2010; accepted 16 June 2010;  
published online 13 July 2010

TNM classification, tumour grading and progression-free survival (PFS), defined as the time from first diagnosis until diagnosis of progressive disease (i.e. local recurrence of the primary lesion, or growth of metastases or occurrence of new metastatic lesions).

### Retroviral infection

IMR90 human fibroblasts (CCI-186 from American Type Culture Collection, Manassas, VA, USA) were stably transduced with the pBabe-Puro-H-RasV12 retrovirus (provided by S Lowe) or an empty vector as a control, and selected in puromycin as described (Serrano *et al*, 1997; Braig *et al*, 2005). Cell pellets were snap frozen in liquid nitrogen or processed as FFPE pellets comparable to patient tissue samples.


### Immunohistochemical analysis

Cryosections (12  $\mu$ m) were acetone fixed and exposed to an anti-Ki67 primary antibody (M7240, 1:250 dilution; Dako, Glostrup, Denmark) for 30 min. Antibody binding was visualised by a chromogenic substrate in a streptavidin/alkaline phosphatase-amplified secondary antibody according to the manufacturer's recommendations (K0689, K0698, K0625, X3021, all from Dako).

FFPE sections (7  $\mu$ m) were subjected to heat-induced antigen retrieval before incubation with primary antibodies for 30 min. Primary antibodies against Ki67 (as above), heterochromatin

protein 1 $\gamma$  (HP1 $\gamma$ ; MAB3450, 1:250 dilution; Chemicon/Millipore, Billerica, MA, USA), phospho-activated ERK1/2 (p-ERK, no. 4376, 1:50 dilution; Cell Signaling Technology, Danvers, MA, USA), plasminogen activator inhibitor-1 (PAI-1 (i.e. Ncl-PAI-1), 1:20 dilution; Novocastra, Newcastle upon Tyne, UK) or cleaved caspase-3/Asp175 (no. 9661, 1:200 dilution; Cell Signaling Technology) were used, followed by the appropriate secondary antibody along with a streptavidin/alkaline phosphatase conjugate or streptavidin/peroxidase kit and suitable chromogenic substrates such as 3,3'-diaminobenzidine or Fast Red (K0690, K3468, K5005, all from Dako).

The formula and the cut-off values of the SI were generated based on the expression (i.e. the percentage of positive cells by immunostaining) of the three markers p-ERK, HP1 $\gamma$  and PAI-1 in low-proliferating areas (arbitrarily defined as <12 Ki67-positive in an area of 100 cells) in a learning set of five adenoma samples. For each of the three markers, a factor was generated that reflects the reciprocal percentage of cells that stained positive in such areas averaged over these five adenomas. This factor was used as a coefficient to equalise the marker's relative individual contribution to the SI. Moreover, a linear correction value was added to set the discrimination threshold to 0. Values between -1 and +1 were considered 'non-conclusive'. Senescence index values of individual cancer samples were obtained in low-proliferating areas as well (see Figure 2 for further information on SI-related technical procedures).



**Figure 1** Stratification of stage IV CRC samples by a senescence index (SI) predicts PFS to first-line 5-FU/LV therapy. **(A)** Proportions of senescent cases in cryo-preserved colorectal tissue sections of the indicated groups (normal crypt mucosa ( $n=5$ , 0 senescent); adenoma ( $n=12$ , 8 senescent), invasive carcinoma ( $n=6$ , 1 senescent)). Note that 9 out of 12 adenoma and 2 out of 6 carcinoma cases would score 'senescent' if judged in low-proliferating areas only (see **D**). **(B)** Average frequency of senescent cells per group (as in **A**), measured as the percentage of SA- $\beta$ -gal-positive (blue) cells, and compared to the rate of Ki67-positive (red nuclear staining) cells (top: error bars represent the standard deviation; bottom: matched areas of representative photomicrographs – a non-senescent normal crypt mucosa, a senescent adenoma and a formally non-senescent carcinoma (but showing numerous senescent cells)). Notably, in normal colorectal mucosa, only cells of the most differentiated luminal mucosa stain SA- $\beta$ -gal-positive. **(C)** FFPE sections of pelleted Ras-infected senescent (sen.) human fibroblasts (SA- $\beta$ -gal-positive and Ki67-negative frozen material as a reference) show much stronger immunoreactivity for p-ERK, HP1 $\gamma$  and cytoplasmic PAI-1 when compared with non-senescent (non-sen.) mock-infected fibroblasts. **(D)** SI values, based on the expression of these three markers, were obtained in 30 cases of stage IV CRC specimens at diagnosis, and used to stratify PFS following 5-FU/LV first-line chemotherapy (senescent ( $n=12$ ; blue line) vs non-senescent ( $n=17$ ; red line); one case scored 'not conclusive' (see Figure 2B)). Genomic sequencing in a subset of these 29 specimens identified K-Ras codon 12 or 13 mutations in 5 out of 6 senescent, but only 2 out of 11 non-senescent cases (inset). Note that a primary stratification by the K-Ras mutation status unveiled no significant differences in PFS ( $P=0.128$ ).

## Senescence-associated $\beta$ -galactosidase activity

Senescence-associated  $\beta$ -galactosidase activity was detected at pH 6.0 in cryo-preserved cells or tissue sections as described (Dimri *et al*, 1995; Braig *et al*, 2005). Cases were considered senescent if their mean percentage of SA- $\beta$ -gal-positive cells was higher than the mean percentage of Ki67-positive cells.

## Ras mutation analysis

Genomic DNA was extracted from macro-dissected tumour areas of FFPE tissue sections using the QIAamp DNA Mini kit (Qiagen, Hilden, Germany). PCR amplification of the first exon of the *k-ras* gene was performed according to van den Brandt and colleagues (Brink *et al*, 2003). The resulting 179 bp PCR product was sequenced using the BigDye Terminator v1.1 Cycle Sequencing kit on a 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA). Hotspot codon 12 or 13 mutations were detected by comparison with the germ-line sequence.


## Statistical analysis

Statistical analyses (SPSS software package, release 17.0; SPSS, Munich, Germany) of Kaplan–Meier survival plots were based on the log-rank (Mantel–Cox) test; additional statistical comparisons used the Wilcoxon–Mann–Whitney test (to probe equal distribution of age, frequency of Ki67-reactive and cleaved caspase-3-positive cells, and serum CEA levels in patient subgroups), the Fisher's exact test (with respect to gender, tumour localisation, sites of distant metastasis (one *vs* more than one) and *Ras* mutations) and the  $\chi^2$ -test (regarding the pT and the pN status). *P*-values <0.05 were considered statistically significant.

## RESULTS

We analysed 23 snap-frozen colorectal tissue samples of normal mucosa, adenomas and untreated invasive carcinomas by the SA- $\beta$ -gal assay, complemented by immunostaining for the proliferation marker Ki67 and confirmed the reportedly high frequency of senescent cells in adenomas, leading to the classification of 8 out of 12 adenoma cases tested as senescent, which is well in line with their macroscopic presentation as polyps of often stable size for years (Figure 1A and B; see the flow diagram in Figure 2A for technical details) (Bartkova *et al*, 2006). Importantly, as previously reported for a subset of lymphoma, lung and breast cancer specimens at manifestation (te Poele *et al*, 2002; Roberson *et al*, 2005; Reimann *et al*, 2010), we detected a significant fraction of senescent cells within neoplastic epithelial areas of manifest colorectal carcinomas, possibly indicating a still available senescence programme at this full-blown cancer stage (Figure 1A and B).

Because the enzymatic SA- $\beta$ -gal assay cannot be applied to FFPE routine samples, or substituted by a single marker, we tested protein expression levels of a panel of DDR mediators, cell-cycle regulators, chromatin-related proteins and others (Bartkova *et al*, 2006; Collado and Serrano, 2006) in a well-established OIS reference model system – sections of either snap-frozen or FFPE pellets of Ras-senescent *vs* proliferating fibroblasts – that allowed us to compare SA- $\beta$ -gal staining and potential immunohistochemical surrogate markers in the same material side by side (Serrano *et al*, 1997). Using this fibroblast model system followed by first a learning and then a validation set of adenoma samples, we generated a senescence surrogate score (SI) based on the expression of p-ERK, HP1 $\gamma$  and PAI-1 – all of them previously linked to OIS (Serrano *et al*, 1997; Lin *et al*, 1998; Narita *et al*, 2003) – that recapitulated SA- $\beta$ -gal reactivity and adenoma senescence (Figure 1C; Figure 2).



**Figure 2** Generation and validation of the senescence index (SI). **(A)** Technical flow diagram of the generation and application of the SI in a Ras-transduced human fibroblast cell line and in colorectal tissue specimens. **(B)** Formula and cut-off values of the SI based on the expression p-ERK, HP1 $\gamma$  and PAI-1. Coefficients reflect the reciprocal average percentage of cells that stained positive for the respective marker in the learning adenomas to normalise the relative weight of the three markers. The correction value -19 was chosen to set the discrimination threshold at 0, with the range between -1 and +1 considered 'non-conclusive'. **(C)** The majority of validation set adenomas is senescent when analysed by the SI. A set of seven matched samples (frozen and FFPE material from the same adenoma) underscores the high concordance between the SA- $\beta$ -gal/Ki67- (see definition in Materials and Methods section) and the SI-based assignment.

We obtained the SI in low-proliferating areas of 30 independent UICC stage IV CRC samples before any drug treatment, and assigned these cases, based on a cut-off value, to a (partly) senescent *vs* a non-senescent group. All patients in this retrospective analysis received a 5-FU/LV-based first-line regimen. Patients with senescent areas in their tumour biopsies experienced a significantly longer PFS with a median PFS of 12.0 *vs* 6.0 months when compared to the non-senescent group (Figure 1D). Notably, both groups did not show statistically significant differences regarding gender, age, pT and pN status as well as localisation of the primary tumour (colon *vs* rectum), extent of distant metastasis (one *vs* more than one site) or CEA serum levels at diagnosis, and showed indistinguishable rates of proliferation (i.e. averaged sample-wide Ki67 reactivity) and apoptosis (i.e. mean frequency of cleaved caspase-3-positive cells) (data not shown). Interestingly, K-Ras codon 12/13 mutations were found at a higher frequency ( $P=0.035$ ) in the senescent group (Figure 1D, inset), suggesting that Ras mutations, if associated with a senescent phenotype, may not necessarily serve as a predictor of poor outcome, as reported by several studies in the past (Benhattar *et al*, 1993; Andreyev *et al*, 1998, 2001; Roth *et al*, 2010).

## DISCUSSION

This is the first report linking cellular senescence at diagnosis to treatment outcome in cancer. Whether sporadic senescent cells in manifest tumours represent a few remainders of the pre-malignant condition, or indicate retained senescence susceptibility

throughout the tumour is currently not clear. Our study data favour the latter explanation, postulating that TIS produced in response to DNA-damaging chemotherapy in senescence-capable tumour cells contributes to the overall outcome to therapy. Notably, an inverse correlation between the expression level of another senescence marker, macroH2A, and the risk of recurrence has recently been reported for lung cancer patients (Zhang *et al*, 2005; Sporn *et al*, 2009). Additional studies are certainly needed to clarify whether a greater extent of sporadic cancer cell senescence indeed translates into a higher frequency of TIS-positive cells *in situ* when analysed in re-biopsies a few days after chemotherapy. Moreover, a preserved pro-senescent cancer capability might be therapeutically exploitable by novel senescence-inducing strategies that do no longer damage DNA. The role of senescent cells at diagnosis as a novel predictor of treatment outcome should be further evaluated in larger prospective trials.

## ACKNOWLEDGEMENTS

We thank Gabriele Fernahl and Simone Spieckermann for technical assistance; Soyoung Lee and other members of the Schmitt lab for helpful discussions. This study was supported in part by Grant no. 108789 from the Deutsche Krebshilfe to CAS.

## Conflict of interest

The authors declared no conflict of interest.

## REFERENCES

- Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT, O'Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij AF, Arends JW, Andersen SN, Lovig T, Breivik J, Gaudernack G, Clausen OP, De Angelis PD, Meling GI, Rognum TO, Smith R, Goh HS, Font A, Rosell R, Sun XF, Zhang H, Benhattar J, Losi L, Lee JQ, Wang ST, Clarke PA, Bell S, Quirke P, Bubb VJ, Piris J, Cruickshank NR, Morton D, Fox JC, Al-Mulla F, Lees N, Hall CN, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo VE, Finkelstein SD, Thebo JS, Senagore AJ, Halter SA, Wadler S, Malik S, Krtolica K, Urosevic N (2001) Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. *Br J Cancer* **85**: 692–696
- Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA (1998) Kirsten ras mutations in patients with colorectal cancer: the multicenter 'RASCAL' study. *J Natl Cancer Inst* **90**: 675–684
- Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldborg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J, Bartek J (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. *Nature* **434**: 864–870
- Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N, Vassiliou LV, Kolettas E, Niforou K, Zoumpourlis VC, Takaoka M, Nakagawa H, Tort F, Fugger K, Johansson F, Sehested M, Andersen CL, Dyrskjot L, Orntoft T, Lukas J, Kittas C, Helleday T, Halazonetis TD, Bartek J, Gorgoulis VG (2006) Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. *Nature* **444**: 633–637
- Benhattar J, Losi L, Chaubert P, Givel JC, Costa J (1993) Prognostic significance of K-ras mutations in colorectal carcinoma. *Gastroenterology* **104**: 1044–1048
- Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B, Stein H, Dörken B, Jenuwein T, Schmitt CA (2005) Oncogene-induced senescence as an initial barrier in lymphoma development. *Nature* **436**: 660–665
- Brink M, de Goeij AF, Weijenberg MP, Roemen GM, Lentjes MH, Pachen MM, Smits KM, de Bruine AP, Goldbohm RA, van den Brandt PA (2003) K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. *Carcinogenesis* **24**: 703–710
- Brown JM, Attardi LD (2005) The role of apoptosis in cancer development and treatment response. *Nat Rev Cancer* **5**: 231–237
- Chang BD, Broude EV, Dokmanovic M, Zhu H, Ruth A, Xuan Y, Kandel ES, Lausch E, Christov K, Roninson IB (1999) A senescence-like phenotype distinguishes tumor cells that undergo terminal proliferation arrest after exposure to anticancer agents. *Cancer Res* **59**: 3761–3767
- Collado M, Serrano M (2006) The power and the promise of oncogene-induced senescence markers. *Nat Rev Cancer* **6**: 472–476
- Collado M, Serrano M (2010) Senescence in tumours: evidence from mice and humans. *Nat Rev Cancer* **10**: 51–57
- Dimri GP, Lee X, Basile G, Acosta M, Scott G, Roskelley C, Medrano EE, Linskens M, Rubelj I, Pereira-Smith O (1995) A biomarker that identifies senescent human cells in culture and in aging skin *in vivo*. *Proc Natl Acad Sci USA* **92**: 9363–9367
- Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Dittullo Jr RA, Kastrinakis NG, Levy B, Kletsas D, Yoneta A, Herlyn M, Kittas C, Halazonetis TD (2005) Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. *Nature* **434**: 907–913
- Lin AW, Barradas M, Stone JC, van Aelst L, Serrano M, Lowe SW (1998) Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. *Genes Dev* **12**: 3008–3019
- Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS (2005) BRAF600-associated senescence-like cell cycle arrest of human naevi. *Nature* **436**: 720–724
- Narita M, Nunez S, Heard E, Lin AW, Hearn SA, Spector DL, Hannon GJ, Lowe SW (2003) Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. *Cell* **113**: 703–716
- Reimann M, Lee S, Loddenkemper C, Dörr JR, Tabor V, Aichele P, Stein H, Dörken B, Jenuwein T, Schmitt CA (2010) Tumor stroma-derived TGF-beta limits Myc-driven lymphomagenesis via Suv39h1-dependent senescence. *Cancer Cell* **17**: 262–272



- Roberson RS, Kussick SJ, Vallieres E, Chen SY, Wu DY (2005) Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. *Cancer Res* **65**: 2795–2803
- Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. *J Clin Oncol* **28**: 466–474
- Schmitt CA (2003) Senescence, apoptosis and therapy – cutting the lifelines of cancer. *Nat Rev Cancer* **3**: 286–295
- Schmitt CA (2007) Cellular senescence and cancer treatment. *Biochim Biophys Acta* **1775**: 5–20
- Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM, Lowe SW (2002) A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. *Cell* **109**: 335–346
- Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW (1997) Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. *Cell* **88**: 593–602
- Sporn JC, Kustatscher G, Hothorn T, Collado M, Serrano M, Muley T, Schnabel P, Ladurner AG (2009) Histone macroH2A isoforms predict the risk of lung cancer recurrence. *Oncogene* **28**: 3423–3428
- te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP (2002) DNA damage is able to induce senescence in tumor cells *in vitro* and *in vivo*. *Cancer Res* **62**: 1876–1883
- Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA (2010) Ki67 in breast cancer: prognostic and predictive potential. *Lancet Oncol* **11**: 174–183
- Zhang R, Poustovoitov MV, Ye X, Santos HA, Chen W, Daganzo SM, Erzberger JP, Serebriiskii IG, Canutescu AA, Dunbrack RL, Pehrson JR, Berger JM, Kaufman PD, Adams PD (2005) Formation of MacroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. *Dev Cell* **8**: 19–30